Devita, Hellman, and Rosenberg's Cancer

LWBK1006-31 LWW-Govindan-Review December 12, 2011 19:43

Chapter 31•Acute Leukemias 439

Question 31.10. A 70-year-old man presents with newly diagnosed AML-M4 with

eosinophilia. Choice of treatment will be based on all, EXCEPT:

A. His age

B. His performance status

C. His cytogenetics

D. Excellent response to 7+3 induction therapy in the elderly

Question 31.11. You have been following a 54-year-old woman with acute promyelocytic

leukemia (APL) in clinic. After 2 years she returns to clinic with fatigue,

an elevated WBC, and increased promyelocytes. Peripheral blood PCR

confirms recurrence of her t(15;17) translocation. Before starting arsenic

salvage therapy you obtain which test?

A. Liver function test

B. Erythrocyte sedimentation rate

C. D-dimer

D. Electrocardiogram

Question 31.12. You have been caring for a 65-year-old woman with a distant history of

breast cancer treated with adjuvant cyclophosphamide and Adriamycin.

During the last year, she developed progressive anemia and thrombo-

cytopenia. She also recently developed leukopenia. Her bone marrow

biopsy shows decreased cellularity with dysplastic features and 25%

blasts. Which of the following cytogenetic changes might you expect to

find?

A. t(15;17)

B. t(9;21)

C. Complex cytogenetics

D. Trisomy 21

Question 31.13. All of the following statements are true regarding elderly patients (age

>60 years) with AML, EXCEPT?

A. In general, older patients with AML have poor outcomes when com-

pared to younger patients.

B. Treatment with low-dose cytarabine leads to better outcomes than

best supportive care.

C. Single-agent tipifarnib treatment did not improve survival compared

to best supportive care alone.

D. Treatment with decitabine leads to better survival outcomes com-

pared to low-dose cytarabine.